Navigation Links
Cardiogenesis Reports Third Quarter 2009 Results
Date:11/10/2009

IRVINE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products used in the treatment of patients suffering from severe angina, today reported financial results for its third quarter ended September 30, 2009.

Net revenues in the third quarter of 2009 totaled $2,134,000 an 18% decrease from prior year third quarter net revenues of $2,618,000. The decrease in sales was primarily attributed to the absence of laser sales during the three month period ended September 30, 2009 as compared to laser sales of $373,000 for the three months ended September 30, 2008.

Net revenues in the first nine months of 2009 totaled $7,222,000, a 26% decrease from net revenues of $9,719,000 in the first nine months of 2008. Laser sales decreased $1,832,000 and handpiece sales decreased $786,000 as compared to the prior year nine month period.

"We continue to make progress in our efforts to re-engage the cardiology community and to refocus our sales force on utilization of previously installed lasers. We are taking the right steps to increase our core TMR business," said Paul McCormick, Executive Chairman. He continued, "At the same time we are stepping up our investment in research and development as we prepare to initiate a U.S. clinical trial for our PHOENIX(TM) Combination Delivery System, which permits the intramyocardial delivery of both TMR and stem cells. Based upon our recent meeting with the FDA we expect to make our IDE submission by the end of the year."

The Company reported a third quarter 2009 operating loss of $718,000 as compared with an operating loss of $310,000 in the prior year quarter. The net loss for the quarter was $739,000 or $0.02 per basic and diluted share, as compared with net loss of $308,000, or $0.01 per basic and diluted share in the 2008 third quarter.

For the first nine months of 2009, Cardiogenesis reported an operating loss of $1,577,000 as compared with operating income of $235,000 for the same period in 2008. The net loss for the first nine months of 2009 was $1,643,000 or $0.04 per basic and diluted share, compared with net income of $258,000, or $0.01 per basic and diluted share, for the first nine months of 2008.

Gross margin was 82% of net revenues for the quarters ended September 30, 2009 and 2008. Gross profit decreased by $390,000 to $1,754,000 for the current year third quarter as compared with $2,144,000 for the 2008 third quarter.

For the nine months ended September 30, 2009, gross margin was 82% of net revenues as compared to 84% for the nine months ended September 30, 2008. Gross profit in absolute dollars decreased by $2,215,000 to $5,915,000 for the nine months ended September 30, 2009, as compared to $8,130,000 for the nine months ended September 30, 2008. The decrease in the gross margin percentage for the three months and nine month periods was primarily attributed to a decrease in laser sales.

Research and development expenses were $379,000 in the third quarter of 2009 as compared with $165,000 in the 2008 third quarter. Year to date, R&D expenses of $1,013,000 were $380,000 or 60% above the prior year period of $633,000. The dollar increase for the three month and nine month periods are primarily attributed to regulatory expenses incurred for FDA submissions.

Sales and marketing expenses of $1,363,000 in the quarter ended September 30, 2009 decreased $173,000, or 11%, compared with $1,536,000 for the quarter ended September 30, 2008. For the nine months ended September 30, 2009, sales and marketing expenditures totaled $4,104,000, a decrease of $754,000, or 16%, compared with $4,858,000 for the nine months ended September 30, 2008. The decrease in sales and marketing expenditures for both the third quarter and nine month periods ended September 30, 2009 as compared to the corresponding prior year periods, was primarily due to lower commissions and related employee expenses. In addition, travel expenses for the nine months ended September 30, 2009 were $151,000 lower than the first nine months of 2008.

General and administrative expenses for the quarter ended September 30, 2009 totaled $730,000 as compared to $753,000 during the quarter ended September 30, 2008. For the nine months ended September 30, 2009, general and administrative expenses totaled $2,375,000 as compared to $2,404,000 for the nine months ended September 30, 2008.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that treat severe angina. Our market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR).

For more information on Cardiogenesis and its products, please visit our website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.

Safe Harbor Statement

This press release contains forward-looking statements, including, without limitation, with respect to the Company's expectation to file an IDE for the Company's PHOENIX(TM) Combination Delivery System. Any forward-looking statements in this news release are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's other filings with the Securities and Exchange Commission. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

                           CARDIOGENESIS CORPORATION
                      CONDENSED CONSOLIDATED STATEMENTS OF
                                 OPERATIONS
                    (in thousands, except per share amounts)
                                   (unaudited)

                                       Three months ended   Nine months ended
                                           September 30,      September 30,
                                         2009        2008     2009     2008
                                         ----        ----     ----     ----
    Net revenues                       $2,134      $2,618   $7,222   $9,719
    Cost of revenues                      380         474    1,307    1,589
                                          ---         ---    -----    -----
          Gross profit                  1,754       2,144    5,915    8,130
                                        -----       -----    -----    -----
    Operating expenses:
        Research and development          379         165    1,013      633
        Sales and marketing             1,363       1,536    4,104    4,858
        General and administrative        730         753    2,375    2,404
                                          ---         ---    -----    -----
          Total operating expenses      2,472       2,454    7,492    7,895
                                        -----       -----    -----    -----
          Operating income (loss)        (718)       (310)  (1,577)     235
    Other income (expense):
    Interest expense                       (4)         (1)     (35)     (22)
    Interest income                         1          13        3       55
    Other non-operating expense           (20)          -      (20)       -
                                         ----         ---     ----      ---
    Total other income (expense), net     (23)         12      (52)      33
                                         ----         ---     ----      ---
          Income (loss) before
           income taxes                  (741)       (298)  (1,629)     268
    Provision for income taxes             (2)         10       14       10
                                          ---         ---      ---      ---
          Net income (loss)              (739)       (308)  (1,643)     258
                                        =====       =====  =======      ===
    Net earnings (loss) per share:
       Basic                           $(0.02)     $(0.01)  $(0.04)   $0.01
                                       ======      ======   ======    =====
       Diluted                         $(0.02)     $(0.01)  $(0.04)   $0.01
                                       ======      ======   ======    =====

    Weighted average shares
      outstanding:
       Basic                           45,549      45,292   45,519   45,292
                                       ------      ------   ------   ------
       Diluted                         45,549      45,292   45,519   45,328
                                       ------      ------   ------   ------



                        CARDIOGENESIS CORPORATION
                  CONDENSED CONSOLIDATED BALANCE SHEETS
                              (in thousands)


                                                        September   December
                                                           30,         31,
                                                          2009        2008
                                                       (unaudited)  (audited)
                                                        ----------   --------
                                    ASSETS
    Current assets:
       Cash and cash equivalents                          $2,517      $2,907
       Accounts receivable, net of allowance
        for doubtful accounts of $7 and $20,
        respectively                                         941       1,330
      Inventories                                            984       1,164
      Investments in marketable securities                     -          75
       Prepaids and other current assets                     356         395
                                                             ---         ---
          Total current assets                             4,798       5,871
    Property and equipment, net                              350         382
    Other assets, net                                         18          18
                                                             ---         ---
          Total assets                                    $5,166      $6,271
                                                          ======      ======

                     LIABILITIES AND SHAREHOLDERS' EQUITY
     Current liabilities:
       Accounts payable                                     $338        $200
       Accrued liabilities                                 1,020       1,103
       Deferred revenue                                      971         800
       Note payable                                          140           -
       Current portion of capital lease
        obligations                                            9           6
                                                             ---         ---
          Total current liabilities                        2,478       2,109
    Capital lease obligations, less current portion           16          13
                                                             ---         ---
          Total liabilities                                2,494       2,122
                                                           -----       -----

     Commitments and Contingencies

    Shareholders' equity:
       Preferred stock:
        no par value; 5,000 shares authorized;
        none issued and outstanding                            -           -
       Common stock:
        no par value; 75,000 shares authorized;
        45,549 and 45,487 shares issued and
        outstanding, respectively                        174,165     173,999
       Accumulated deficit                              (171,493)   (169,850)
                                                       ---------   ---------
          Total shareholders' equity                       2,672       4,149
                                                           -----       -----
          Total liabilities and shareholders'
           equity                                         $5,166      $6,271
                                                          ======      ======


SOURCE Cardiogenesis Corporation


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
2. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
3. Vion Pharmaceuticals Reports 2009 Third Quarter and Nine-Month Results
4. PLC Systems Reports Third Quarter 2009 Results; Announces Distribution Agreement for RenalGuard(R) in Brazil
5. Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results
6. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
7. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
8. Osteotech Reports Third Quarter 2009 Financial Results
9. Air Methods Reports 3Q2009 Results and 4Q2009 Update
10. Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
11. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Kalifornien, 12. Februar 2016  Sequent Medical, Inc. ... von Patienten für eine Studie zur Sicherheit und ... speziell für die Behandlung von rupturierten intrakraniellen Aneurysmen ... Leiter der Neuroradiologie an der Universitätsklinik Bicètre in ... der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
(Date:2/12/2016)... 2016  Eli Lilly and Company (NYSE: LLY ) ... (pemetrexed disodium) vitamin regimen patent would not presently be infringed ... France , Italy and ... only with dextrose solution.  --> ... of Appeal held that Lilly,s patent would be indirectly infringed ...
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 2016 , ... Miami Dental Specialists is excited to bring patients the choice ... in January, Miami Dental Specialists will offer the non-metal implants as a safe, holistic ... be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer Care” ... Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 ...
(Date:2/12/2016)... ... 12, 2016 , ... Homeowners now have a next generation ... America’s leading brand of building products, has improved upon its industry-best array of ... version of the ColorView® Exterior Style and Color Selector. Created expressly for the ...
(Date:2/12/2016)... ... ... Healthcare careers in the medical laboratory, nursing, and in the imaging field ... staffing leader Aureus Medical Group during the month of January. Aureus Medical specializes in ... and in travel and direct hire opportunities in other allied health fields. , The ...
(Date:2/12/2016)... ... February 12, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... what he says are the real facts surrounding all those Bible stories. For generations ... Sunday school teachers, and Yisrayl says there is more to these than just mere ...
Breaking Medicine News(10 mins):